Identification by Reverse Vaccinology of Three Virulence Factors in Burkholderia cenocepacia That May Represent Ideal Vaccine Antigens

Irudal, Samuele; Scoffone, Viola Camilla; Trespidi, Gabriele; Barbieri, Giulia; Viglio, Simona; Pizza, Mariagrazia; Scarselli, María; Riccardi, Giovanna; Buroni, Silvia

doi:10.3390/vaccines11061039

Cited by 4 publications

(2 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The disc diffusion method provides low reproducibility for Bcc members [ 7 ]. Therefore, more expensive or time-consuming techniques, such as the E-test or the broth dilution and agar dilution methods, have been suggested [ 7 , 37 , 40 , 57 ].…”

Section: Determination Of the Antimicrobial Susceptibility Of ...mentioning

confidence: 99%

Burkholderia cepacia complex in cystic fibrosis: critical gaps in diagnosis and therapy

Gutiérrez Santana,

Coria Jiménez

2024

Annals of Medicine

View full text Add to dashboard Cite

Burkholderia cepacia complex ( Bcc ) is a bacterial group with ‘natural’ multi-antimicrobial resistance. This complex has generated epidemic outbreaks across the world. In people with cystic fibrosis (CF), Bcc can cause severe lung infections that lead to accelerated lung damage, which can be complicated by necrotizing pneumonia accompanied by high fevers, leucocytosis, and bacteraemia, which commonly causes fatal outcomes. Specifically, infection by Burkholderia cenocepacia is considered an exclusion criterion for lung transplantation. The species of Bcc exhibit both genetic and phenotypic hypervariability that complicate their accurate microbiological identification. Automated methods such as MALDI-TOF can err in the determination of species. Their slow growth even in selective agars and the absence of international consensuses on the optimal conditions for their isolation make early diagnosis a difficult challenge to overcome. The absence of correlations between antibiograms and clinical results has resulted in the absence of standardized cut-off values of antimicrobial susceptibility, a fact that brings a latent risk since incorrect antibiotic therapy can induce the selection of more aggressive variants that worsen the clinical picture of the host, added to the absence of a clear therapeutic guide for the eradication of pulmonary infections by Bcc in patients with CF, resulting in frequently ineffective treatments. There is an urgent need to standardize methods and diagnostic tools that would allow an early and accurate diagnosis, as well as to perform clinical studies of the effectiveness of available antibiotics to eradicate Bcc infections, which would allow us to establish standardized therapeutic schemes for Bcc -infected patients.

show abstract

Section: Determination Of the Antimicrobial Susceptibility Of ...mentioning

confidence: 99%

Burkholderia cepacia complex in cystic fibrosis: critical gaps in diagnosis and therapy

Gutiérrez Santana,

Coria Jiménez

2024

Annals of Medicine

View full text Add to dashboard Cite

show abstract

“…Therefore, some researchers have proposed repurposing Bpc-specific vaccines to treat Bcc infections as a feasible and economically viable solution [ 45 , 46 , 47 ]. One study recently broke down the cost effectiveness of developing and testing a melioidosis-specific vaccine, ultimately concluding it to be a cost-effective strategy of reducing disease incidence [ 48 ].…”

Section: Introductionmentioning

confidence: 99%

Burkholderia pseudomallei Complex Subunit and Glycoconjugate Vaccines and Their Potential to Elicit Cross-Protection to Burkholderia cepacia Complex

Badten,

Torres

2024

Vaccines

View full text Add to dashboard Cite

Burkholderia are a group of Gram-negative bacteria that can cause a variety of diseases in at-risk populations. B. pseudomallei and B. mallei, the etiological agents of melioidosis and glanders, respectively, are the two clinically relevant members of the B. pseudomallei complex (Bpc). The development of vaccines against Bpc species has been accelerated in recent years, resulting in numerous promising subunits and glycoconjugate vaccines incorporating a variety of antigens. However, a second group of pathogenic Burkholderia species exists known as the Burkholderia cepacia complex (Bcc), a group of opportunistic bacteria which tend to affect individuals with weakened immunity or cystic fibrosis. To date, there have been few attempts to develop vaccines to Bcc species. Therefore, the primary goal of this review is to provide a broad overview of the various subunit antigens that have been tested in Bpc species, their protective efficacy, study limitations, and known or suspected mechanisms of protection. Then, we assess the reviewed Bpc antigens for their amino acid sequence conservation to homologous proteins found in Bcc species. We propose that protective Bpc antigens with a high degree of Bpc-to-Bcc sequence conservation could serve as components of a pan-Burkholderia vaccine capable of protecting against both disease-causing groups.

show abstract

Repurposing promethazine hydrochloride to inhibit biofilm formation against Burkholderia thailandensis

Xu,

You,

Wang

et al. 2024

Med Microbiol Immunol

View full text Add to dashboard Cite

Identification by Reverse Vaccinology of Three Virulence Factors in Burkholderia cenocepacia That May Represent Ideal Vaccine Antigens

Cited by 4 publications

References 84 publications

Burkholderia cepacia complex in cystic fibrosis: critical gaps in diagnosis and therapy

Burkholderia cepacia complex in cystic fibrosis: critical gaps in diagnosis and therapy

Burkholderia pseudomallei Complex Subunit and Glycoconjugate Vaccines and Their Potential to Elicit Cross-Protection to Burkholderia cepacia Complex

Repurposing promethazine hydrochloride to inhibit biofilm formation against Burkholderia thailandensis

Contact Info

Product

Resources

About